Compass Pathways Saham

Compass Pathways P/B

P/B (Rasio Harga terhadap Nilai Buku) dari Compass Pathways (CMPS) pada 22 Jul 2026 adalah 3,65. Tahun sebelumnya, P/B (Rasio Harga terhadap Nilai Buku) adalah 2,50 — perubahan sebesar 45,93% (lebih tinggi).

P/B

3,65

YoY

45,93%

Terakhir Diperbarui:

P/B (Rasio Harga terhadap Nilai Buku) dari Compass Pathways adalah 2026 3,65 . P/B (Rasio Harga terhadap Nilai Buku) dari Compass Pathways adalah 2025 2,50 . Menurun 45,93% lebih tinggi dibandingkan dengan tahun sebelumnya.
Access this data via the Eulerpool API

Compass Pathways Analisis saham

Apa yang dilakukan Compass Pathways? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways adalah salah satu perusahaan paling populer di Eulerpool.

Pertanyaan yang Sering Diajukan tentang saham Compass Pathways

P/B (Rasio Harga terhadap Nilai Buku) Compass Pathways adalah 3,65 pada tahun 2026.

Access this data via the Eulerpool API

Penilaian — Compass Pathways

Semua Metrik Kunci — Compass Pathways